Stock Track | Bristol-Myers Squibb Soars 5.06% Intraday on Strong Q4 Earnings and Upbeat 2026 Guidance

Stock Track

Feb 05

Bristol-Myers Squibb's stock surged 5.06% during intraday trading on Thursday, driven by the company's fourth-quarter 2025 financial results that exceeded Wall Street expectations and its optimistic outlook for 2026.

The biopharma company reported adjusted earnings per share of $1.26 for the fourth quarter, beating the consensus estimate of $1.12. Quarterly revenue rose 1% to $12.5 billion, also topping analysts' forecast of $12.28 billion. The strong performance was supported by robust sales of cancer immunotherapy Opdivo, which saw a 9% increase to $2.69 billion, ahead of expectations.

Furthermore, Bristol-Myers provided full-year 2026 guidance that surpassed analyst estimates. The company projects revenue in the range of $46.0 billion to $47.5 billion, compared to the consensus of $44.2 billion, and expects adjusted earnings per share between $6.05 and $6.35, above the estimated $6.02. The company anticipates its blood thinner Eliquis to be an important growth driver, with worldwide revenue expected to increase 10% to 15% in 2026, as strategic price cuts are designed to avoid U.S. Medicare penalties and drive volume growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1198859314"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1198859314\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1198859314?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198859314","market":"nz","top_or_hot":-1,"title":"Stock Track | Bristol-Myers Squibb Soars 5.06% Intraday on Strong Q4 Earnings and Upbeat 2026 Guidance","media":"Stock Track","content":"<p>Bristol-Myers Squibb's stock surged 5.06% during intraday trading on Thursday, driven by the company's fourth-quarter 2025 financial results that exceeded Wall Street expectations and its optimistic outlook for 2026.</p><p>The biopharma company reported adjusted earnings per share of $1.26 for the fourth quarter, beating the consensus estimate of $1.12. Quarterly revenue rose 1% to $12.5 billion, also topping analysts' forecast of $12.28 billion. The strong performance was supported by robust sales of cancer immunotherapy Opdivo, which saw a 9% increase to $2.69 billion, ahead of expectations.</p><p>Furthermore, Bristol-Myers provided full-year 2026 guidance that surpassed analyst estimates. The company projects revenue in the range of $46.0 billion to $47.5 billion, compared to the consensus of $44.2 billion, and expects adjusted earnings per share between $6.05 and $6.35, above the estimated $6.02. The company anticipates its blood thinner Eliquis to be an important growth driver, with worldwide revenue expected to increase 10% to 15% in 2026, as strategic price cuts are designed to avoid U.S. Medicare penalties and drive volume growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bristol-Myers Squibb Soars 5.06% Intraday on Strong Q4 Earnings and Upbeat 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bristol-Myers Squibb Soars 5.06% Intraday on Strong Q4 Earnings and Upbeat 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-05 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bristol-Myers Squibb's stock surged 5.06% during intraday trading on Thursday, driven by the company's fourth-quarter 2025 financial results that exceeded Wall Street expectations and its optimistic outlook for 2026.</p><p>The biopharma company reported adjusted earnings per share of $1.26 for the fourth quarter, beating the consensus estimate of $1.12. Quarterly revenue rose 1% to $12.5 billion, also topping analysts' forecast of $12.28 billion. The strong performance was supported by robust sales of cancer immunotherapy Opdivo, which saw a 9% increase to $2.69 billion, ahead of expectations.</p><p>Furthermore, Bristol-Myers provided full-year 2026 guidance that surpassed analyst estimates. The company projects revenue in the range of $46.0 billion to $47.5 billion, compared to the consensus of $44.2 billion, and expects adjusted earnings per share between $6.05 and $6.35, above the estimated $6.02. The company anticipates its blood thinner Eliquis to be an important growth driver, with worldwide revenue expected to increase 10% to 15% in 2026, as strategic price cuts are designed to avoid U.S. Medicare penalties and drive volume growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMY","symbol_name":"施贵宝","start_time":0,"source_url":"","article_id":"1198859314","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198859314","pubTimestamp":1770303461,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Bristol-Myers Squibb's stock surged 5.06% during intraday trading on Thursday, driven by the company's fourth-quarter 2025 financial results that exceeded Wall Street expectations and its optimistic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMY":"施贵宝"},"translate_title":"个股追踪|百时美施贵宝盘中大涨5.06%，得益于强劲的Q4盈利和乐观的2026年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1},"content_text":"Bristol-Myers Squibb's stock surged 5.06% during intraday trading on Thursday, driven by the company's fourth-quarter 2025 financial results that exceeded Wall Street expectations and its optimistic outlook for 2026.The biopharma company reported adjusted earnings per share of $1.26 for the fourth quarter, beating the consensus estimate of $1.12. Quarterly revenue rose 1% to $12.5 billion, also topping analysts' forecast of $12.28 billion. The strong performance was supported by robust sales of cancer immunotherapy Opdivo, which saw a 9% increase to $2.69 billion, ahead of expectations.Furthermore, Bristol-Myers provided full-year 2026 guidance that surpassed analyst estimates. The company projects revenue in the range of $46.0 billion to $47.5 billion, compared to the consensus of $44.2 billion, and expects adjusted earnings per share between $6.05 and $6.35, above the estimated $6.02. The company anticipates its blood thinner Eliquis to be an important growth driver, with worldwide revenue expected to increase 10% to 15% in 2026, as strategic price cuts are designed to avoid U.S. Medicare penalties and drive volume growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}